Aptamer Group PLC (AIM:APTA) (Aptamer Group PLC (AIM:APTA)) has reported major strides in its collaborations with Unilever, Neuro-Bio, and AstraZeneca, underlining the growing potential of its advanced biological binders.
“All of the programmes, from fast-moving consumer goods to therapeutics, continue to show excellent results with increased validation and progression towards commercial products that will deliver a value inflexion point [for the company], said CEO, Dr Arron Tolley.
With Unilever, Aptamer is advancing a deodorant formulation using Optimer binders.
Recent tests showed the binders remain stable on human skin for over 72 hours and effectively inhibit enzymes that cause odour. This success moves the project closer to commercialisation in a deodorant market valued at over $21 billion annually.
Its tie-up with Neuro-Bio has achieved a breakthrough in developing an Alzheimer’s diagnostic test. The test uses Optimer binders to detect Alzheimer’s biomarkers in spinal fluid and saliva samples, distinguishing patients from healthy individuals.
Efforts are underway to adapt this …